Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

@article{Attard2005SelectiveBO,
  title={Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer},
  author={G. Attard and A. Belldegrun and J. D. de Bono},
  journal={BJU International},
  year={2005},
  volume={96}
}
  • G. Attard, A. Belldegrun, J. D. de Bono
  • Published 2005
  • Medicine
  • BJU International
  • Prostate cancer is the most common malignancy in Western societies and the second most common cause of male cancerrelated death in the UK and USA, accounting for ≈ 12% of all male cancer-related deaths [1,2]. When confined to the prostate gland, the disease is curable with local therapy (radical prostatectomy, external beam radiotherapy, brachytherapy or cryotherapy). However, despite the use of PSA for screening, in 15–33% of men local therapy fails and they develop incurable metastatic… CONTINUE READING
    176 Citations

    Topics from this paper.

    Abiraterone in Prostate Cancer: A New Angle to an Old Problem
    • 40
    • PDF
    Anti-Androgen Abiraterone Acetate Improves the Therapeutic Efficacy of Statins on Castration-Resistant Prostate Cancer Cells.
    • 2
    • PDF

    References

    SHOWING 1-10 OF 37 REFERENCES
    The evolving role of estrogen therapy in prostate cancer.
    • W. Oh
    • Medicine
    • Clinical prostate cancer
    • 2002
    • 80
    Collocation of androgen receptor gene mutations in prostate cancer.
    • 193
    • PDF
    Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer.
    • 16
    Molecular determinants of resistance to antiandrogen therapy
    • 2,122
    The Androgen Axis in Recurrent Prostate Cancer
    • 660
    • PDF
    Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
    • E. Small, S. Halabi, +7 authors N. Vogelzang
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2004
    • 492
    Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17α-hydroxylase/C17–20 lyase)
    • 197